Stocktoria
EXAGEN INC. XGN
EXAGEN INC. (XGN) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $66.6M at a -30.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.599 |
| Retained earnings / assets | -5.417 |
| EBIT / assets | -0.242 |
| Equity / liabilities | 0.43 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| XGN | EXAGEN INC. | 3/9 | -14.91 | — | +19.7% |
| PSNL | Personalis, Inc. | 3/9 | 0.31 | — | -17.7% |
| BNR | Burning Rock Biotech Ltd | 5/9 | -11.46 | — | +9.2% |
| BDSX | BIODESIX INC | 3/9 | -19.59 | — | +24.1% |
| CFOR | CapForce Inc. | 2/9 | -14.09 | 1 | — |
| BGLC | BioNexus Gene Lab Corp | 4/9 | 13.26 | — | — |
| YDES | YD Bio Ltd | 1/9 | -1.35 | — | — |
About EXAGEN INC.
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
FAQ
Is XGN financially healthy?
EXAGEN INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does XGN pay a dividend?
No, EXAGEN INC. does not currently pay a dividend.
How profitable is XGN?
In FY2025, EXAGEN INC. had a net margin of -30.0% and a return on equity of -114.3%.
What is the analyst price target for XGN?
The average Wall-Street price target for EXAGEN INC. is $8.57, about 30.1% above the recent price, from 7 analysts (consensus: strong buy).
Is XGN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on EXAGEN INC.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.